机构:[1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy , Chengdu 610041, People's Republic of China.四川大学华西医院[2]Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH) , Bethesda, Maryland 20892, United States.[3]State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University , Xiamen 361005, People's Republic of China.
Exendin-4 has been clinically exploited for treating type 2 diabetes, but the short circulation half-life and multiple daily injections limit its widespread application with respect to poor patient compliance, low efficacy, and high treatment cost. In this study, a potent long-acting release system based on biomimetic mineralization was constructed for biocompatible and sustained exendin-4 delivery. Similar to natural biomineralization, exendin-4 can be mineralized to form nanosized mineral solids by means of the reaction between acidic amino acid residues and calcium ions in a supersaturated environment with negligible influence on peptide bioactivity. Mineralized exendin-4 particles may be spontaneously absorbed by a living body under physiologically supersaturated conditions, resulting in gradual dissociation and sustained drug release. In such a way, the glucose level of diabetic mice may be effectively controlled for a long period of time by mineralized exendin-4 without obvious side effects. We believe this biomimetic formulation can serve as a promising candidate for future clinical applications for type 2 diabetes therapies.
基金:
China Postdoctoral
Science Foundation (2015M570745 and 2016T90815), Natural
Science Foundation of Guangdong Province (2016A030310229),
Sichuan Innovative Research Team Program for Young Scientists
(2016TD0004), National Natural Science Foundation of China
(81602634, 31525009), and the Intramural Research Program,
National Institute of Biomedical Imaging and Bioengineering,
National Institutes of Health (ZIA EB000073).
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2017]版:
大类|1 区工程技术
小类|1 区化学综合1 区物理化学1 区材料科学:综合1 区纳米科技
最新[2023]版:
大类|1 区材料科学
小类|1 区化学:综合1 区物理化学1 区材料科学:综合1 区纳米科技
第一作者:
第一作者机构:[1]State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center for Biotherapy , Chengdu 610041, People's Republic of China.[2]Laboratory of Molecular Imaging and Nanomedicine (LOMIN), National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health (NIH) , Bethesda, Maryland 20892, United States.
通讯作者:
推荐引用方式(GB/T 7714):
Chen Wei,Wang Guohao,Yung Bryant C,et al.Long-Acting Release Formulation of Exendin-4 Based on Biomimetic Mineralization for Type 2 Diabetes Therapy.[J].ACS nano.2017,11(5):5062-5069.doi:10.1021/acsnano.7b01809.
APA:
Chen Wei,Wang Guohao,Yung Bryant C,Liu Gang,Qian Zhiyong&Chen Xiaoyuan.(2017).Long-Acting Release Formulation of Exendin-4 Based on Biomimetic Mineralization for Type 2 Diabetes Therapy..ACS nano,11,(5)
MLA:
Chen Wei,et al."Long-Acting Release Formulation of Exendin-4 Based on Biomimetic Mineralization for Type 2 Diabetes Therapy.".ACS nano 11..5(2017):5062-5069